Sanofi and Regeneron Collaborate to Plan Beyond Dupixent

Sanofi (SNY) CEO, Belén Garijo, stated that the company aims to restore trust with Regeneron Pharmaceuticals (REGN) and incorporate additional assets into their existing alliance. Dupixent (dupilumab), co-developed by both companies, is a marketed antibody that blocks the interleukin-4 receptor alpha (IL-4Rα). It received its first FDA approval on March 28, 2017, and has since expanded its indications to include atopic dermatitis and asthma. Following Sanofi's streamlining of programs, including amlitelimab and itepekimab, the expansion of collaboration signifies an effort to re-establish a proven co-development framework as a key driver for future growth, mitigating the risks associated with patent expirations. In the short term, the allocation of rights to new assets and the structure of development cost-sharing will be critical factors determining the alliance's value.

Apnimed IPO Highlights Preference for Late-Stage Clinical Assets

Apnimed (APMD) successfully raised $192 million through an IPO, issuing 12 million shares at $16 per share. This marks the 15th biotech IPO in the U.S. for 2026. The company's lead candidate, AD109, is an oral, once-daily treatment for obstructive sleep apnea (OSA) that combines 2.3mg of aroxbutynin and 75mg of atomoxetine, modulating muscarinic signaling and norepinephrine reuptake, respectively. Having completed two Phase 3 trials, the company has submitted a New Drug Application (NDA) to the FDA, with a PDUFA decision date of February 28, 2027. With standard treatments like CPAP, surgery, oral appliances, and Eli Lilly's (LLY) Zepbound (tirzepatide), which received FDA approval on December 20, 2024, as key competitors, the oral convenience of AD109 represents a significant differentiator.

BMS Reports Strong Earnings, but Key Clinical Timelines Delayed

Bristol Myers Squibb (BMY) reported second-quarter revenue of $12.973 billion, with Eliquis (apixaban) contributing $4.481 billion. However, key results timelines for Cobenfy and milvexian have been delayed. Cobenfy (xanomeline/trospium chloride) is a marketed treatment for schizophrenia that combines M1 and M4 muscarinic receptor agonism with peripheral anticholinergic activity. The Phase 3 ADEPT-2 trial targeting Alzheimer's disease-related psychosis is a critical step in expanding its value. Factor XIa inhibitor milvexian is being evaluated in Phase 3 trials, LIBREXIA-AF and LIBREXIA-STROKE, compared to Eliquis or placebo, with a combined enrollment of over 30,000 patients. Given that Eliquis accounts for 35% of quarterly revenue, the delay in the development of next-generation anticoagulants poses a challenge to the company's post-patent growth trajectory.

AI Partnerships and Litfulo Data Create Additional Options

Relation Therapeutics and GSK (GSK) have entered into a target discovery collaboration, leveraging human cellular perturbation data and multi-omics-based MORGAN models, with a potential value of up to $110 million. The deal includes upfront payments and success-based milestones, focusing on capturing the value of disease biology data and artificial intelligence models rather than acquiring clinical assets. Pfizer's (PFE) Litfulo (ritlecitinib) inhibits JAK3 and TEC family kinases and has demonstrated positive results in two Phase 3 TRANQUILLO trials for non-segmental vitiligo, achieving the co-primary endpoints of facial and total body repigmentation at 52 weeks. The current competitive treatment is Opzelura (ruxolitinib), a topical JAK1/JAK2 inhibitor from Incyte (INCY), which received FDA approval on July 18, 2022. Litfulo is now moving towards global regulatory submissions, targeting the adult oral systemic treatment market for vitiligo.